Related references
Note: Only part of the references are listed.Correlations between in vitro potency of polyethylene glycol-protein conjugates and their chromatographic behavior
Simon Caserman et al.
ANALYTICAL BIOCHEMISTRY (2009)
mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
Heidi A. Lane et al.
CLINICAL CANCER RESEARCH (2009)
Engineered protein scaffolds as next-generation antibody therapeutics
Michaela Gebauer et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2009)
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer
Sean P. Dineen et al.
BMC CANCER (2008)
Targeting angiogenesis in renal cell carcinoma
Georgios Lainakis et al.
CURRENT CANCER DRUG TARGETS (2008)
VEGFR3: A new target for antiangiogenesis therapy?
Timothy P. Padera et al.
DEVELOPMENTAL CELL (2008)
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
Andrea Molckovsky et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2008)
The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics
C. Simone Fishburn
JOURNAL OF PHARMACEUTICAL SCIENCES (2008)
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Scott M. Wilhelm et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Molecular origins of cancer: Tumor angiogenesis
Robert S. Kerbel
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Jeanine M. Roodhart et al.
CURRENT CLINICAL PHARMACOLOGY (2008)
Size comparison between proteins PEGylated with branched and linear Poly(Ethylene glycol) molecules
Conan J. Fee
BIOTECHNOLOGY AND BIOENGINEERING (2007)
VEGF: an essential mediator of both angiogenesis and endochondral ossification
J. Dai et al.
JOURNAL OF DENTAL RESEARCH (2007)
Vascular endothelial growth factors C and D represent novel prognostic markers in colorectal carcinoma using quantitative image analysis
W.-G. Hu et al.
EUROPEAN SURGICAL RESEARCH (2007)
Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro
Elena V. Getmanova et al.
CHEMISTRY & BIOLOGY (2006)
Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF
WC Liang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Vascular endothelial growth factors and receptors in colorectal cancer: Implications for anti-angiogenic therapy
SE Duff et al.
EUROPEAN JOURNAL OF CANCER (2006)
Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two
MH Parker et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2005)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-α2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2
C Dhalluin et al.
BIOCONJUGATE CHEMISTRY (2005)
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
G Bocci et al.
CANCER RESEARCH (2004)
Tumor angiogenesis and accessibility: Role of vascular endothelial growth factor
RK Jain
SEMINARS IN ONCOLOGY (2002)
Directed evolution of high-affinity antibody mimics using mRNA display
LH Xu et al.
CHEMISTRY & BIOLOGY (2002)
Size-exclusion chromatography-multiangle laser light scattering analysis of β-lactoglobulin and bovine serum albumin in aqueous solution with added salt
JAPP van Dijk et al.
JOURNAL OF CHROMATOGRAPHY A (2000)
Share Paper
